Login to Your Account

Vivus Phase III With Alprostadil Aiming At 'Huge' FSAD Market

By Randall Osborne

Monday, September 13, 2004

For reasons that might be as much socio-economic as medical, female sexual arousal disorder (FSAD) has been overlooked in favor of the lucrative market for erectile dysfunction therapies such as the pioneering phosphodiesterase type-5 inhibitor Viagra from Pfizer Inc.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription